Investment Banking

The Quarterly Rx: Q2 2022 U.S. Biopharma Recap

An increase in M&A and financing activity to end biopharma's Q2 have rekindled hope that we’re finally out of the biotech winter, while others fear it’s just a false spring. As companies continue to weather the storm, the focus remains on cash runway, quality news flow/clinical data, and consolidation. William Blair's Biopharma team shares perspectives in The Quarterly Rx: Q2 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

More News and Insights

Quick Reference Guide to Retirement Plans

Understanding the nuances between retirement plans can be challenging. William Blair’s Quick Reference Guide to Retirement Plans compares and contrasts features such as account establishment, account contributions, and accessibility.

Read more

Thinking Differently About Recruiting

While the Blair Connect summer internship program is only two years old, it’s already impacting how we approach recruiting, says Drew Buckley, CFA, partner, and research analyst on the global equity team.

Watch the video

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit